A four-week low-FODMAP diet restored colonic barrier function and reduced mast cell activation in patients with diarrhea-predominant irritable bowel syndrome, according to a mechanistic trial published in Gastroenterology. The study identified fecal lipopolysaccharide as the microbial driver that activates toll-like receptor 4 on colonic mast cells to trigger barrier disruption.
Most patients achieved meaningful symptom reduction
Investigators enrolled 48 adults meeting Rome IV criteria for diarrhea-predominant IBS; 42 completed the structured four-week low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) dietary intervention, European Medical Journal reported.
Barrier function and mast cell markers improved
The magnitude of these physiological changes did not correlate with the magnitude of clinical symptom response, the study authors noted.
Fecal lipopolysaccharide drives TLR4-dependent mast cell activation
Following the four-week diet, fecal lipopolysaccharide levels dropped significantly in correlation with shifts in gram-negative bacterial abundance, the study found.
Removing lipopolysaccharide or administering a toll-like receptor 4 antagonist completely prevented barrier disruption. Barrier dysfunction was absent in TLR4-deficient mice and in mast cell-deficient mice treated with pre-diet fecal supernatants. Reconstituting mast cell-deficient mice with wild-type mast cells restored permeability defects, but reconstitution with TLR4-deficient mast cells did not, the researchers reported.
Mechanistic pathway established
This TLR4-mast cell axis represents the direct mechanistic link between diet, microbiome, and mucosal barrier dysfunction in IBS-D.
Clinical implications for mast cell-targeted therapy
The trial was registered at ClinicalTrials.gov under identifier NCT04542018.
What this means for patients
The study provides biological validation for a dietary approach already widely used in clinical practice, while identifying a specific microbial molecule — lipopolysaccharide — and a host receptor pathway — TLR4 on mast cells — that could be targeted pharmacologically. Many IBS patients report food-related symptoms and prefer dietary treatment over pharmacotherapy, the study background noted.
Longer-term effects and treatment alternatives untested
The trial evaluated a four-week intervention; longer-term sustainability and the durability of barrier restoration after diet liberalization were not assessed. The disconnect between the magnitude of physiological improvement and clinical symptom response also warrants further investigation. Whether mast cell stabilizers or antihistamines can replicate the barrier benefits without dietary restriction remains to be tested in clinical trials.